Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
A phase 2 trial of Tepotinib in non-small-cell lung cancer and small-cell lung cancer, run by EMD Serono Research & Development Institute, Inc., active and no longer recruiting.
Overview
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) is a phase 2 interventional study registered as NCT02864992 by EMD Serono Research & Development Institute, Inc., with 337 participants enrolled, started 2016-09-13 and due to reach its primary completion in 2022-05-16. Interventions recorded: Tepotinib. Conditions listed: Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV. No results are recorded here; the registry entry is the source.
Setting
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Phase
Phase 2
Sponsor
EMD Serono Research & Development Institute, Inc.
Registry
Enrolled
337